Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05098080 · ClinicalTrials.gov registry record · Phase 1
Hutrukin to Analyze Safety and PK in Healthy Volunteers
A Phase 1 study, sponsored by XBiotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05098080 is a Phase 1 study that has completed, run by XBiotech. The registered enrollment target is 24 participants.
The verdict
NCT05098080, a Phase 1 study, has completed, sponsored by XBiotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The study will be a Phase I, open label, safety and pharmacokinetics study of HutrukinTM in at least eight healthy subjects in each of the three dose cohorts (1,000 mg, 3,000 mg and 5,000 mg).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Hutrukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-04-10 |
| Est. Completion | 2024-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05098080
The ClinicalTrials.gov registry entry for NCT05098080 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XBiotech, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05098080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05098080 about?
NCT05098080 is a clinical study titled "Hutrukin to Analyze Safety and PK in Healthy Volunteers". The study will be a Phase I, open label, safety and pharmacokinetics study of HutrukinTM in at least eight healthy subjects in each of the three dose cohorts (1,000 mg, 3,000 mg and 5,000 mg).
What is the current status of trial NCT05098080?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-04-10. Estimated completion is 2024-04-05.
What interventions are being tested in trial NCT05098080?
The interventions under investigation include: Placebo (BIOLOGICAL), Hutrukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT05098080?
This trial is sponsored by XBiotech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.